Literature DB >> 28560786

Medication compliance and clinical outcomes of fixed-dose combinations vs free combinations of an angiotensin II receptor blocker and a calcium channel blocker in hypertension treatment.

Ying-Chang Tung1, Yu-Chang Huang1, Lung-Sheng Wu1, Chee-Jen Chang2, Pao-Hsien Chu1,3,4.   

Abstract

Using the National Health Insurance Research Database of Taiwan, the authors identified 1136 patients taking fixed-dose combination and 4544 patients taking free combinations of an angiotensin II receptor blocker and a dihydropyridine calcium channel blocker from January 2009 to December 2012. At a mean follow-up of 2.1 years, the fixed-dose combination was associated with improved medication adherence and persistence and better survival free from major adverse cardiac events and hospitalization for heart failure compared with the free combination regimens. ©2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  angiotensin II receptor blocker; dihydropyridine calcium channel blocker; fixed-dose combination; hypertension; major adverse cardiac event

Mesh：

Substances：

Year:  2017        PMID： 28560786      PMCID： PMC8030826          DOI： 10.1111/jch.13035

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


  33 in total

Review 1.  Selected major risk factors and global and regional burden of disease.

Authors:  Majid Ezzati; Alan D Lopez; Anthony Rodgers; Stephen Vander Hoorn; Christopher J L Murray
Journal:  Lancet       Date:  2002-11-02       Impact factor: 79.321

2.  Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.

Authors:  Björn Dahlöf; Peter S Sever; Neil R Poulter; Hans Wedel; D Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2005 Sep 10-16       Impact factor: 79.321

Review 3.  Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials.

Authors:  Jan A Staessen; Yan Li; Lutgarde Thijs; Ji-Guang Wang
Journal:  Hypertens Res       Date:  2005-05       Impact factor: 3.872

4.  2015 guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the management of hypertension.

Authors:  Chern-En Chiang; Tzung-Dau Wang; Kwo-Chang Ueng; Tsung-Hsien Lin; Hung-I Yeh; Chung-Yin Chen; Yih-Jer Wu; Wei-Chuan Tsai; Ting-Hsing Chao; Chen-Huan Chen; Pao-Hsien Chu; Chia-Lun Chao; Ping-Yen Liu; Shih-Hsien Sung; Hao-Min Cheng; Kang-Ling Wang; Yi-Heng Li; Fu-Tien Chiang; Jyh-Hong Chen; Wen-Jone Chen; San-Jou Yeh; Shing-Jong Lin
Journal:  J Chin Med Assoc       Date:  2014-12-26       Impact factor: 2.743

5.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

6.  Secular Trends in Prescription Patterns of Single-Pill Combinations of an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Plus a Thiazide Diuretic for Hypertensive Patients in Taiwan.

Authors:  Chih-Neng Hsu; Tzung-Dau Wang
Journal:  Acta Cardiol Sin       Date:  2013-01       Impact factor: 2.672

7.  Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.

Authors:  Simon Thom; Neil Poulter; Jane Field; Anushka Patel; Dorairaj Prabhakaran; Alice Stanton; Diederick E Grobbee; Michiel L Bots; K Srinath Reddy; Raghu Cidambi; Severine Bompoint; Laurent Billot; Anthony Rodgers
Journal:  JAMA       Date:  2013-09-04       Impact factor: 56.272

8.  Hypertension prevalence, awareness, treatment and control in national surveys from England, the USA and Canada, and correlation with stroke and ischaemic heart disease mortality: a cross-sectional study.

Authors:  Michel Joffres; Emanuela Falaschetti; Cathleen Gillespie; Cynthia Robitaille; Fleetwood Loustalot; Neil Poulter; Finlay A McAlister; Helen Johansen; Oliver Baclic; Norm Campbell
Journal:  BMJ Open       Date:  2013-08-30       Impact factor: 2.692

9.  2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Authors:  Giuseppe Mancia; Robert Fagard; Krzysztof Narkiewicz; Josep Redon; Alberto Zanchetti; Michael Böhm; Thierry Christiaens; Renata Cifkova; Guy De Backer; Anna Dominiczak; Maurizio Galderisi; Diederick E Grobbee; Tiny Jaarsma; Paulus Kirchhof; Sverre E Kjeldsen; Stéphane Laurent; Athanasios J Manolis; Peter M Nilsson; Luis Miguel Ruilope; Roland E Schmieder; Per Anton Sirnes; Peter Sleight; Margus Viigimaa; Bernard Waeber; Faiez Zannad; Josep Redon; Anna Dominiczak; Krzysztof Narkiewicz; Peter M Nilsson; Michel Burnier; Margus Viigimaa; Ettore Ambrosioni; Mark Caufield; Antonio Coca; Michael Hecht Olsen; Roland E Schmieder; Costas Tsioufis; Philippe van de Borne; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Denis L Clement; Antonio Coca; Thierry C Gillebert; Michal Tendera; Enrico Agabiti Rosei; Ettore Ambrosioni; Stefan D Anker; Johann Bauersachs; Jana Brguljan Hitij; Mark Caulfield; Marc De Buyzere; Sabina De Geest; Geneviève Anne Derumeaux; Serap Erdine; Csaba Farsang; Christian Funck-Brentano; Vjekoslav Gerc; Giuseppe Germano; Stephan Gielen; Herman Haller; Arno W Hoes; Jens Jordan; Thomas Kahan; Michel Komajda; Dragan Lovic; Heiko Mahrholdt; Michael Hecht Olsen; Jan Ostergren; Gianfranco Parati; Joep Perk; Jorge Polonia; Bogdan A Popescu; Zeljko Reiner; Lars Rydén; Yuriy Sirenko; Alice Stanton; Harry Struijker-Boudier; Costas Tsioufis; Philippe van de Borne; Charalambos Vlachopoulos; Massimo Volpe; David A Wood
Journal:  Eur Heart J       Date:  2013-06-14       Impact factor: 29.983

10.  Fixed-Dose Combinations of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in the Treatment of Hypertension: A Comparison of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors.

Authors:  Fu-Chih Hsiao; Ying-Chang Tung; Shing-Hsien Chou; Lung-Sheng Wu; Chia-Pin Lin; Chun-Li Wang; Yu-Sheng Lin; Chee-Jen Chang; Pao-Hsien Chu
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817
View more
  7 in total

1.  The impact of fixed-dose combination versus free-equivalent combination therapies on adherence for hypertension: a meta-analysis.

Authors:  Li-Ping Du; Zhong-Wei Cheng; Yu-Xuan Zhang; Ying Li; Dan Mei
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-04-27       Impact factor: 3.738

2.  Fixed-dose combination pharmacologic therapy to improve hypertension control worldwide: Clinical perspective and policy implications.

Authors:  Donald J DiPette; Jamario Skeete; Emily Ridley; Norm R C Campbell; Patricio Lopez-Jaramillo; Sandeep P Kishore; Marc G Jaffe; Antonio Coca; Raymond R Townsend; Pedro Ordunez
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-11-27       Impact factor: 3.738

3.  Medication compliance and clinical outcomes of fixed-dose combinations vs free combinations of an angiotensin II receptor blocker and a calcium channel blocker in hypertension treatment.

Authors:  Ying-Chang Tung; Yu-Chang Huang; Lung-Sheng Wu; Chee-Jen Chang; Pao-Hsien Chu
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-05-30       Impact factor: 3.738

4.  Treatment adherence among adult hypertensive patients: a cross-sectional retrospective study in primary care in Romania.

Authors:  Ioan Tilea; Dorina Petra; Septimiu Voidazan; Elena Ardeleanu; Andreea Varga
Journal:  Patient Prefer Adherence       Date:  2018-04-24       Impact factor: 2.711

5.  Fixed-dose vs free-dose combinations for the management of hypertension-An analysis of 81 958 patients.

Authors:  Peter Bramlage; Stefanie Schmidt; Helen Sims
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-02-19       Impact factor: 3.738

6.  2018 Korean Society of Hypertension Guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension.

Authors:  Hae-Young Lee; Jinho Shin; Gheun-Ho Kim; Sungha Park; Sang-Hyun Ihm; Hyun Chang Kim; Kwang-Il Kim; Ju Han Kim; Jang Hoon Lee; Jong-Moo Park; Wook Bum Pyun; Shung Chull Chae
Journal:  Clin Hypertens       Date:  2019-08-01

Review 7.  Does the Polypill Improve Patient Adherence Compared to Its Individual Formulations? A Systematic Review.

Authors:  Ana Baumgartner; Katarina Drame; Stijn Geutjens; Marja Airaksinen
Journal:  Pharmaceutics       Date:  2020-02-22       Impact factor: 6.321
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.